Cargando…

L.I.F.T. study: Prostatic urethral lift for the treatment of LUTS associated with BPH

Detalles Bibliográficos
Autor principal:	Gupta, Saurabh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2014
Materias:	Uroscan
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3989833/ https://www.ncbi.nlm.nih.gov/pubmed/24744530

Ejemplares similares

Botulinum toxin in high-risk BPH patients in retention
por: Reddy, Sreedhar, et al.
Publicado: (2008)

Bladder stone secondary to prostatic urethral lift (PUL) for benign prostatic hyperplasia (BPH)
por: Kang, JiHun
Publicado: (2021)

Urethral reconstructive surgery: Which catheters are better?
por: Suryavanshi, Manav, et al.
Publicado: (2008)

What is the treatment of choice for bulbar urethral strictures which are not an indication for visual internal urethrotomy?
por: Dubey, Deepak, et al.
Publicado: (2008)

Risk factors for persistent stress urinary incontinence after mid-urethral procedures
por: Chawla, Arun, et al.
Publicado: (2008)

Combined dorsal plus ventral double buccal mucosa graft in bulbar urethral reconstruction
por: Chawla, Arun, et al.
Publicado: (2008)

Endocrine treatment in advanced prostate cancer: When to start?
por: Choudhrie, A. V., et al.
Publicado: (2009)

Medium-term efficacy of the prostatic urethral lift
por: Chin, Peter, et al.
Publicado: (2017)

Prostate cancer treatment does not increase the risk of cardiovascular events
por: Khochikar, Makarand V.
Publicado: (2007)

Intraprostatic injection of botulinum toxin A: A promising treatment for patients with benign prostatic hyperplasia
por: Agrawal, S. K., et al.
Publicado: (2009)

Prostatic Urethral Lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study
por: Rukstalis, Daniel, et al.
Publicado: (2018)

Is Prostate Urethral Lift Effective in Patients with Multiple Comorbidities?
por: Ahn, Sun-Tae, et al.
Publicado: (2022)

Defining the role of antioxidants in the prevention of prostate cancer
por: Pathak, Hemant R., et al.
Publicado: (2009)

Lutetium-177 prostate-specific membrane antigen-617 theranostics: New therapeutic hope in metastatic castrate-resistant prostate cancer?
por: Ranjan, Satish Kumar
Publicado: (2020)

Transurethral ethanol ablation for symptomatic benign prostatic hyperplasia
por: Gautam, Gagan, et al.
Publicado: (2007)

The current role of Active Surveillance in early prostate cancer
por: Shrinivas, R. P., et al.
Publicado: (2009)

Search for new α1a-adrenoceptor-selective antagonist for treating lower urinary tract symptoms associated with benign prostatic hyperplasia
por: Khurana, Naval, et al.
Publicado: (2007)

Safety and efficacy of active surveillance in patients with localized prostate cancer
por: Mavuduru, Ravimohan, et al.
Publicado: (2008)

Relugolix – The novel oral androgen deprivation therapy for prostate cancer
por: Jena, Rahul
Publicado: (2020)

Rezvilutamide for metastatic castration-sensitive prostate cancer: CHART trial
por: Singh, Kirti
Publicado: (2023)

A novel approach to management of nocturia in patients with benign prostatic hyperplasia
por: Sengottayan, Vengetesh K., et al.
Publicado: (2009)

Is incidence of prostate cancer higher in patients with end stage renal disease?
por: Khochikar, Makarand V.
Publicado: (2007)

PROFOUND trial –a new era in targeted therapeutics for prostate carcinoma
por: Tosh, Jyoti Mohan
Publicado: (2022)

STHLM3-MRI study: Role of magnetic resonance imaging-targeted biopsy in prostate cancer screening
por: Gaur, Abhay S.
Publicado: (2022)

Are we along the path for laparoscopic partial nephrectomy?
por: Khurana, Naval, et al.
Publicado: (2007)

Prostatic urethral lift: A minimally invasive treatment for benign prostatic hyperplasia
por: Garcia, Cindy, et al.
Publicado: (2015)

Apalutamide: A novel therapy for non metastatic castration-resistant carcinoma prostate
por: Jayasimha, Sudhindra
Publicado: (2018)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

Triple therapy for metastatic castration sensitive prostate cancer: PEACE-1 trial
por: Singh, Kirti
Publicado: (2022)

Survival following primary androgen deprivation therapy among men with localized prostate cancer
por: Vasudeva, Pawan, et al.
Publicado: (2008)

Thulium laser versus standard transurethral resection of the prostate: A randomized prospective trial
por: Dubey, Deepak, et al.
Publicado: (2008)

Multiparametric magnetic resonance imaging-targeted biopsies in the detection of clinically significant prostate cancer
por: Charalampos, Fragkoulis
Publicado: (2020)

TITAN trial; shifting focus from hormone-refractory to hormone-sensitive prostate cancer
por: Kumar, Gautam
Publicado: (2020)

Benefit of cabazitaxel in previously treated metastatic castration-resistant prostate cancer; CARD trial
por: Mishra, Ankit
Publicado: (2020)

PROMPTS Trial: Screening spinal magnetic resonance imaging in castration-resistant prostate cancer
por: Pattnaik, Soumya Shivasis
Publicado: (2023)

Does dutasteride reduce perioperative blood loss and postoperative complications after transurethral resection of the prostate?
por: Shanmugasundaram, R., et al.
Publicado: (2007)

VISION trial: (177)Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer
por: Rohith, Gorrepati
Publicado: (2021)

PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH
por: Gacci, M., et al.
Publicado: (2013)

A game changing LATITUDE: Role of abiraterone plus prednisolone in metastatic hormone-sensitive prostate cancer
por: Sharma, Aditya Prakash
Publicado: (2017)

The role of 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: Is it the new beginning
por: Agrawal, Sumit
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0poaokl826tvbvmta2rq3p49an